T he emerging field of cardio-oncology involves assessment of cardiovascular disease specific to patients with or surviving cancer (1). Cancer survivors experience a 5-fold increase in the risk for developing heart failure, myocardial infarction, pericardial disease, or valvular abnormalities compared with their siblings without cancer (2). Each disease process may be noninvasively assessed with cardiovascular magnetic resonance (CMR) to establish a diagnosis or to guide therapy to address cardiovascular disease (Central Illustration) (3-5). In this report, we review the use of CMR for assessing the heart and surrounding structures in patients with or surviving cancer suspected of having cardiac abnormalities.
THE ROLE OF CMR IN PATIENTS WITH MALIGNANCIES
Several cardiac abnormalities may result from cancer or its treatment that promote a CMR evaluation 
LV DYSFUNCTION
To date, LVEF is the most widely used measure for identifying LV dysfunction resulting from the administration of cancer therapeutics (14, 15) . Early cardio-oncology studies identified that declines in LVEF after anthracycline administration are associated with development of congestive heart failure (16) . Noninvasively, LVEF may be measured using radionuclide multiple-gated acquisition, 2-dimensional (2D) and 3-dimensional (3D) TTE, cardiac computed tomography, and CMR (5, [17] [18] [19] [20] [21] .
Reductions in LVEF after anthracycline treatment were first observed with radionuclide multiple-gated acquisition scans in the 1970s (16, 22) . Because radionuclide multiple-gated acquisition and cardiac computed tomography incorporate ionizing radiation, a limitation in patients who may be exposed to ionizing radiation exposure for treatment of their cancer, the use of TTE and CMR is increasingly preferred for performing serial measurements of LVEF during receipt of potentially cardiotoxic chemotherapy (23) .
CMR measures of LVEF are most frequently quantified from a contiguous short-axis series of slices spanning the cardiac apex to its base using a steady-state free precession cine white-blood imaging technique ( Table 2) (14) .
Similar algorithms are proposed for surveillance of patients with cancer and survivors (14) .
CMR is of particular advantage in this population because of its high spatial and temporal resolution, reproducibility, and accuracy for LVEF quantification to detect subclinical declines in LVEF, which may occur as early as 1 month after the receipt of cardiotoxic therapies (26, 27) . Videos 1, 2, 3, and 4). In a subsequent analysis on a subset of these same subjects, Jordan et al. (38) observed that 16% of patients may experience deterioration in myocardial circumferential strain due to isolated declines in LVEDV (38) . These data reflect the fact that LV myocardial strain measures Jordan et al. Therefore, the finding of increased early gadolinium enhancement using T1-weighted images is consistent with myocarditis (Table 4 ). An alternative approach is to incorporate a T1-weighted segmented inversion- Using magnetic resonance, TLVDS is characterized by regional LV segmental akinesis that most frequently involves the LV apex ( Table 5) . For those patients experiencing recovery of LV systolic function, LGE is often absent (57) . In addition to patients with TLVDS experiencing increases in serum troponins, they may or may not experience increased signal on T2-weighted images or increased T2 mapping values (58) . These particular imaging findings suggest a transient increase in water uptake within the myocardium that in other disease processes is consistent with an inflammatory condition.
In summary, it is important to recognize that TLVDS occurs in patients with cancer, resulting in LV dysfunction and an increase in LV myocardial T2
without LGE. The mechanisms associating TLVDS with cancer are incompletely understood.
Human epidermal growth factor receptor 2 receptor blocker down-regulation of myocardial contractility. . Trastuzumab cardiotoxicity presents along a spectrum from asymptomatic decline in LVEF to symptomatic heart failure ( Table 6) . A study by 
Research is ongoing for the predictive value of CMR
LGE and longitudinal and radial strain and strain rate as early detectors of cardiac damage (67-71). Tables 1, 4 , and 6. Jordan et al. Most studies describing RV dysfunction in patients with cancer involve survivors of pediatric months after initiating chemotherapy were independently associated with worsening heart failure (116) .
Results from studies such as this suggest that further research should be performed to investigate the impact of potential cardiotoxic chemotherapy on LV mass. CMR may have an important role in this research, as with tissue characterization techniques, one may be able to differentiate the etiology of LV mass declines (e.g., myocellular injury, decreases in myocellular size [117] , or changes in the amount of interstitial fibrosis relative to myocyte number or size).
ADDITIONAL CMR EVALUATIONS IN PATIENTS WITH CANCER
It is important to recognize that CMR may be useful 
FUTURE DIRECTIONS
Moving forward, there are several unanswered questions in the emerging field of cardio-oncology for which CMR may play an important role. First, it is increasingly recognized that exercise intolerance and fatigue contribute to cardiovascular morbidity among those with or surviving cancer (132, 133) . For many years, it was believed that reductions in exerciseassociated cardiac output due to diminished LV performance were the primary contributor to decreased exercise capacity in those treated for cancer (134) .
However, recent data suggest that reductions in exercise-associated arteriovenous oxygen difference may also contribute to the reduction in exercise Third, it is increasingly recognized that many patients treated for cancer experience cognitive dysfunction (139) . At present, the mechanism of cognitive decline in patients with cancer is not well described. In other disease processes, the combination of cardiac large-vessel (aorta) and cerebral microcirculatory and central nervous system structural imaging has been implemented to identify largeand small-vessel vascular disorders associated with cognitive decline (140) . As yet, these techniques have not been implemented in patients with cancer. Investigations using these techniques may provide insight into the cognitive decline observed in patients with cancer.
Finally, CMR measures have not been readily adopted into position or guideline statements related to the management of patients receiving potentially cardiotoxic or renovascular-toxic cancer treatments.
As CMR-derived measures of myocardial mass, mapping, and vascular function become more widespread, research to determine the optimal incorporation of these measures into statements related to management of patients with cancer are warranted. 
CONCLUSIONS

